echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > JAMA: The influence of traditional synthetic anti-rheumatic drugs on the risk of relapse

    JAMA: The influence of traditional synthetic anti-rheumatic drugs on the risk of relapse

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint inflammation, which can lead to joint damage and impaired body function.


    Rheumatoid Arthritis Immunity Recently, researchers have investigated the effect of gradual reduction of csDMARDs on the risk of relapse in RA patients who have achieved sustained remission compared with continued maintenance treatment.


    ARCTIC REWIND is a multi-center, randomized, parallel, open non-inferiority study carried out in 10 hospitals in Norway.


    The average age of the patients was 55.


    In the csDMARD dose halved group, 19 patients (25%) had relapses, while the csDMARD dose stabilized group had only 5 patients (6%).


    Studies believe that for patients with rheumatoid arthritis who have received traditional synthetic anti-rheumatic drugs to improve their condition, the risk of recurrence increases after the drug dose is reduced by half during the maintenance treatment period.


    For patients with rheumatoid arthritis who received traditional synthetic anti-rheumatic drugs and their condition was relieved, the risk of recurrence increased after the drug dose was reduced by half during the maintenance treatment period.


    Original source

    Siri Lillegraven et al.


    com/journals/jama/article-abstract/2779548" target="_blank" rel="noopener">Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission The ARCTIC REWIND Randomized Clinical Trial Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease in Patients With Rheumatoid Arthritis Flares in Remission at the ARCTIC REWIND Randomized Clinical Trial JAMA

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.